2027 Q1 - tulosraportti
47 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 208 | - | - | ||
| 1 069 | - | - | ||
| 3 500 | - | - | ||
| 1 520 | - | - | ||
| 1 500 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q2 - tulosraportti 17.12. |
| Menneet tapahtumat | ||
|---|---|---|
2027 Q1 - tulosraportti 9.9. | ||
2026 Q4 - tulosraportti 17.6. | ||
2026 Q3 - tulosraportti 18.3. | ||
2026 Q2 - tulosraportti 18.12.2025 | ||
2026 Q1 - tulosraportti 11.9.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·2 päivää sittenVery interesting distribution of purchases in the emission: "The outcome shows that approximately 49.97 percent of the offered shares have been subscribed with the support of subscription rights, approximately 21.14 percent have been subscribed without the support of subscription rights, and approximately 28.89 percent will be allocated to HDF Cancer Monitoring BV ("HDF") in its capacity as a guarantor in the Rights Issue. The Rights Issue is thus fully subscribed." Unusually large "over-subscription" from existing shareholders' side (21 %), even though there was no discount on the price relative to the market price of the ordinary share, which some days could be obtained a percent cheaper or more. And only one guarantor - with an exciting name - which perhaps indicates that guarantor will not sell off the acquired shares. We thus stand - PERHAPS - in a completely special situation, where the price of the share is not pushed down after the emission - as is normal with emissions in the biotech sector. It will be exciting to see.
·23.9.New board with clear USA focus. The issue guaranteed to 100% by existing major shareholders. Advanced negotiations with big pharma companies.
·10.9.yet another one of those small crappy Swedish biotech companies that again and again burn through money and have to ask us shareholders for more money time and again they claim 1 year ago they thought they had control over the capital and could manage those small crappy SwedesYou get terribly depressed, but what do you do when you're stuck with a lot of shares and it's absolutely not the time to sell. I think you simply have to forget that you own them and be pleasantly surprised in a few years if something has happened.- ·9.9.Terribly poor press releases written by people who clearly don't have a clue about what information is essential. I calculated the same thing, which I was afterwards informed of by AI: AI summary It requires 3 subscription rights to subscribe for 1 new B-share in Biovica International at the subscription price of 0.30 SEK. [1] (https://www.accessnewswire.com/newsroom/en/biotechnology/biovica-resolves-on-a-fully-guaranteed-rights-issue-of-sek-29.2-million-1218672), [2] (https://www.morningstar.com/news/accesswire/1218672msn/biovica-resolves-on-a-fully-guaranteed-rights-issue-of-sek-292-million)According to the terms of the rights issue (decided on September 9, 2026):Allocation: Each existing share owned on the record date (October 5, 2026) gives 1 subscription right.Ratio: 3 subscription rights entitle to purchase 1 new B-share.Price: The subscription price is set at 0.30 SEK per share. [1] (https://mfn.se/a/biovica-international/biovica-beslutar-om-en-fullt-garanterad-foretradesemission-om-29-2-msek), [2] (https://www.placera.se/pressmeddelanden/biovica-international-biovica-beslutar-om-en-fullt-garanterad-foretradesemission-om-29-2-msek-20260909), [3] (https://www.accessnewswire.com/newsroom/en/biotechnology/biovica-resolves-on-a-fully-guaranteed-rights-issue-of-sek-29.2-million-1218672)The subscription period runs from October 7 to and including October 21, 2026. [1] (https://www.placera.se/pressmeddelanden/biovica-international-biovica-beslutar-om-en-fullt-garanterad-foretradesemission-om-29-2-msek-20260909) I could surely also have found the information with the company, but, taught by bad experience, mistakenly thought this time that when the most essential information was not in the press releases, it was because the company had not clearly communicated it.
·10.7.Now I have bought a couple more lotto tickets.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2027 Q1 - tulosraportti
47 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 päivää sittenVery interesting distribution of purchases in the emission: "The outcome shows that approximately 49.97 percent of the offered shares have been subscribed with the support of subscription rights, approximately 21.14 percent have been subscribed without the support of subscription rights, and approximately 28.89 percent will be allocated to HDF Cancer Monitoring BV ("HDF") in its capacity as a guarantor in the Rights Issue. The Rights Issue is thus fully subscribed." Unusually large "over-subscription" from existing shareholders' side (21 %), even though there was no discount on the price relative to the market price of the ordinary share, which some days could be obtained a percent cheaper or more. And only one guarantor - with an exciting name - which perhaps indicates that guarantor will not sell off the acquired shares. We thus stand - PERHAPS - in a completely special situation, where the price of the share is not pushed down after the emission - as is normal with emissions in the biotech sector. It will be exciting to see.
- ·23.9.New board with clear USA focus. The issue guaranteed to 100% by existing major shareholders. Advanced negotiations with big pharma companies.
- ·10.9.yet another one of those small crappy Swedish biotech companies that again and again burn through money and have to ask us shareholders for more money time and again they claim 1 year ago they thought they had control over the capital and could manage those small crappy SwedesYou get terribly depressed, but what do you do when you're stuck with a lot of shares and it's absolutely not the time to sell. I think you simply have to forget that you own them and be pleasantly surprised in a few years if something has happened.
- ·9.9.Terribly poor press releases written by people who clearly don't have a clue about what information is essential. I calculated the same thing, which I was afterwards informed of by AI: AI summary It requires 3 subscription rights to subscribe for 1 new B-share in Biovica International at the subscription price of 0.30 SEK. [1] (https://www.accessnewswire.com/newsroom/en/biotechnology/biovica-resolves-on-a-fully-guaranteed-rights-issue-of-sek-29.2-million-1218672), [2] (https://www.morningstar.com/news/accesswire/1218672msn/biovica-resolves-on-a-fully-guaranteed-rights-issue-of-sek-292-million)According to the terms of the rights issue (decided on September 9, 2026):Allocation: Each existing share owned on the record date (October 5, 2026) gives 1 subscription right.Ratio: 3 subscription rights entitle to purchase 1 new B-share.Price: The subscription price is set at 0.30 SEK per share. [1] (https://mfn.se/a/biovica-international/biovica-beslutar-om-en-fullt-garanterad-foretradesemission-om-29-2-msek), [2] (https://www.placera.se/pressmeddelanden/biovica-international-biovica-beslutar-om-en-fullt-garanterad-foretradesemission-om-29-2-msek-20260909), [3] (https://www.accessnewswire.com/newsroom/en/biotechnology/biovica-resolves-on-a-fully-guaranteed-rights-issue-of-sek-29.2-million-1218672)The subscription period runs from October 7 to and including October 21, 2026. [1] (https://www.placera.se/pressmeddelanden/biovica-international-biovica-beslutar-om-en-fullt-garanterad-foretradesemission-om-29-2-msek-20260909) I could surely also have found the information with the company, but, taught by bad experience, mistakenly thought this time that when the most essential information was not in the press releases, it was because the company had not clearly communicated it.
- ·10.7.Now I have bought a couple more lotto tickets.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 208 | - | - | ||
| 1 069 | - | - | ||
| 3 500 | - | - | ||
| 1 520 | - | - | ||
| 1 500 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q2 - tulosraportti 17.12. |
| Menneet tapahtumat | ||
|---|---|---|
2027 Q1 - tulosraportti 9.9. | ||
2026 Q4 - tulosraportti 17.6. | ||
2026 Q3 - tulosraportti 18.3. | ||
2026 Q2 - tulosraportti 18.12.2025 | ||
2026 Q1 - tulosraportti 11.9.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2027 Q1 - tulosraportti
47 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q2 - tulosraportti 17.12. |
| Menneet tapahtumat | ||
|---|---|---|
2027 Q1 - tulosraportti 9.9. | ||
2026 Q4 - tulosraportti 17.6. | ||
2026 Q3 - tulosraportti 18.3. | ||
2026 Q2 - tulosraportti 18.12.2025 | ||
2026 Q1 - tulosraportti 11.9.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 päivää sittenVery interesting distribution of purchases in the emission: "The outcome shows that approximately 49.97 percent of the offered shares have been subscribed with the support of subscription rights, approximately 21.14 percent have been subscribed without the support of subscription rights, and approximately 28.89 percent will be allocated to HDF Cancer Monitoring BV ("HDF") in its capacity as a guarantor in the Rights Issue. The Rights Issue is thus fully subscribed." Unusually large "over-subscription" from existing shareholders' side (21 %), even though there was no discount on the price relative to the market price of the ordinary share, which some days could be obtained a percent cheaper or more. And only one guarantor - with an exciting name - which perhaps indicates that guarantor will not sell off the acquired shares. We thus stand - PERHAPS - in a completely special situation, where the price of the share is not pushed down after the emission - as is normal with emissions in the biotech sector. It will be exciting to see.
- ·23.9.New board with clear USA focus. The issue guaranteed to 100% by existing major shareholders. Advanced negotiations with big pharma companies.
- ·10.9.yet another one of those small crappy Swedish biotech companies that again and again burn through money and have to ask us shareholders for more money time and again they claim 1 year ago they thought they had control over the capital and could manage those small crappy SwedesYou get terribly depressed, but what do you do when you're stuck with a lot of shares and it's absolutely not the time to sell. I think you simply have to forget that you own them and be pleasantly surprised in a few years if something has happened.
- ·9.9.Terribly poor press releases written by people who clearly don't have a clue about what information is essential. I calculated the same thing, which I was afterwards informed of by AI: AI summary It requires 3 subscription rights to subscribe for 1 new B-share in Biovica International at the subscription price of 0.30 SEK. [1] (https://www.accessnewswire.com/newsroom/en/biotechnology/biovica-resolves-on-a-fully-guaranteed-rights-issue-of-sek-29.2-million-1218672), [2] (https://www.morningstar.com/news/accesswire/1218672msn/biovica-resolves-on-a-fully-guaranteed-rights-issue-of-sek-292-million)According to the terms of the rights issue (decided on September 9, 2026):Allocation: Each existing share owned on the record date (October 5, 2026) gives 1 subscription right.Ratio: 3 subscription rights entitle to purchase 1 new B-share.Price: The subscription price is set at 0.30 SEK per share. [1] (https://mfn.se/a/biovica-international/biovica-beslutar-om-en-fullt-garanterad-foretradesemission-om-29-2-msek), [2] (https://www.placera.se/pressmeddelanden/biovica-international-biovica-beslutar-om-en-fullt-garanterad-foretradesemission-om-29-2-msek-20260909), [3] (https://www.accessnewswire.com/newsroom/en/biotechnology/biovica-resolves-on-a-fully-guaranteed-rights-issue-of-sek-29.2-million-1218672)The subscription period runs from October 7 to and including October 21, 2026. [1] (https://www.placera.se/pressmeddelanden/biovica-international-biovica-beslutar-om-en-fullt-garanterad-foretradesemission-om-29-2-msek-20260909) I could surely also have found the information with the company, but, taught by bad experience, mistakenly thought this time that when the most essential information was not in the press releases, it was because the company had not clearly communicated it.
- ·10.7.Now I have bought a couple more lotto tickets.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 208 | - | - | ||
| 1 069 | - | - | ||
| 3 500 | - | - | ||
| 1 520 | - | - | ||
| 1 500 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt